患者年龄与薄黑色素瘤淋巴结阳性率的相关性
基于美国国家癌症数据库2010-2013年8772例接受宽切除及区域淋巴结手术评估的临床I期0.50-1.0mm薄黑色素瘤患者,回顾性分析发现总体淋巴结阳性率为3.8%(95%CI 3.4%-4.2%)。多变量分析显示年轻年龄、女性、厚度≥0.76mm、Clark分级增高、核分裂、溃疡及淋巴血管侵犯与淋巴结阳性独立相关;决策树分析中年龄是核分裂和厚度之后的重要风险分层因素。
要点
- 薄黑色素瘤患者总体淋巴结阳性率为3.8%(95%CI 3.4%-4.2%)。
- 年轻年龄与淋巴结阳性独立相关,是传统病理因素之外的重要风险分层因素。
- 年龄<40岁、T1b、0.50-0.75mm者淋巴结阳性率5.6%(95%CI 3.3%-8.6%),通常不推荐前哨淋巴结活检。
核心结论
- 患者年龄是估计薄黑色素瘤淋巴结阳性的重要因素,独立于传统病理因素。
- 选择淋巴结活检患者时应考虑年龄。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库(代表1500余家医院),纳入2010-2013年8772例临床I期0.50-1.0mm薄黑色素瘤患者,均接受宽切除及区域淋巴结手术评估。
主要发现
- 总体淋巴结阳性率为3.8%(95%CI 3.4%-4.2%),333例有淋巴结转移。
- 淋巴结阴性患者中位年龄56岁(IQR 46-67),阳性患者中位年龄52岁(IQR 41-61),P < .001。
- 多变量分析中,年轻年龄、女性、厚度≥0.76mm、Clark分级增高、核分裂、溃疡及淋巴血管侵犯与淋巴结阳性独立相关。
- 决策树分析中,年龄是核分裂和厚度之后的重要风险分层因素。
- 年龄<40岁、T1b、0.50-0.75mm者淋巴结阳性率5.6%(95%CI 3.3%-8.6%);年龄≥65岁、T1b、≥0.76mm者阳性率仅3.9%(95%CI 2.7%-5.3%)。
关键数值与推荐
- 年龄分组:<40岁、40-64岁、≥65岁用于多变量分析。
- 厚度分组:0.76mm或更大与0.50-0.75mm。
- T1b肿瘤定义未在原文摘要中详述。
临床怎么用
- 评估薄黑色素瘤患者是否行前哨淋巴结活检时,除病理因素外应纳入年龄。
- 年轻患者即使厚度0.50-0.75mm且通常不推荐活检,也可能有较高淋巴结阳性率,需个体化决策。
- 老年患者即使厚度≥0.76mm且通常推荐活检,淋巴结阳性率可能较低,需权衡利弊。
局限性
- 回顾性研究设计。
- 原文摘要未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: More than half of all new melanoma diagnoses present as clinically localized T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in this population given the overall low yield. Guidelines for SLNB have focused on pathologic factors, but patient factors, such as age, are not routinely considered. OBJECTIVES: To identify indicators of lymph node (LN) metastasis in thin melanoma in a large, generalizable data set and to evaluate the association between patient age and LN positivity. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study using the National Cancer Database, an oncology database representing patients from more than 1500 hospitals throughout the United States, was performed (2010-2013). Data analysis was conducted from October 1, 2016, to January 15, 2017. A total of 8772 patients with clinical stage I 0.50 to 1.0 mm thin melanoma undergoing wide excision and surgical evaluation of regional LNs were included for study. MAIN OUTCOME AND MEASURES: The primary outcome of interest was presence of melanoma in a biopsied regional LN. Clinicopathologic factors associated with LN positivity were characterized, using logistic regression. Age was categorized as younger than 40 years, 40 to 64 years, and 65 years or older for multivariable analysis. Classification tree analysis was performed to identify high-risk groups for LN positivity. RESULTS: Among the study cohort (n = 8772), 333 patients had nodal metastases, for an overall positivity rate of 3.8% (95% CI, 3.4%-4.2%). A total of 4087 (54.0%) patients were women. Median age was 56 years (interquartile range [IQR], 46-67) in patients with negative LNs and 52 years (IQR, 41-61) in those with positive LNs (P < .001). In multivariable analysis, younger age, female sex, thickness of 0.76 mm or larger, increasing Clark level, mitoses, ulceration, and lymphovascular invasion were independently associated with LN positivity. In decision tree analysis, patient age was identified as an important risk stratifier for LN metastases, after mitoses and thickness. Patients younger than 40 years with category T1b tumors 0.50 to 0.75 mm, who would generally not be recommended for SLNB, had an LN positivity rate of 5.6% (95% CI, 3.3%-8.6%); conversely, patients 65 years or older with T1b tumors 0.76 mm or larger, who would generally be recommended for SLNB, had an LN positivity rate of only 3.9% (95% CI, 2.7%-5.3%). CONCLUSIONS AND RELEVANCE: Patient age is an important factor in estimating lymph node positivity in thin melanoma independent of traditional pathologic factors. Age therefore should be taken into consideration when selecting patients for nodal biopsy.
引用
- Sinnamon AJ, Neuwirth MG, Yalamanchi P, et al. Association Between Patient Age and Lymph Node Positivity in Thin Melanoma. JAMA Dermatol. 2017. PMID: 28724122. doi:10.1001/jamadermatol.2017.2497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。